Cross Country Healthcare (CCRN)
Market Price (12/4/2025): $9.45 | Market Cap: $307.0 MilSector: Health Care | Industry: Health Care Facilities
Cross Country Healthcare (CCRN)
Market Price (12/4/2025): $9.45Market Cap: $307.0 MilSector: Health CareIndustry: Health Care Facilities
Investment Highlights
Why It Matters
Which of these 2 stories sounds closer for this stock?
1. Generates cash flow
The stock generated 4% or more of the share price (called cash flow yield), and shows moderate 10-15% or more growth.
2. Riding a trend
Think Tesla during the pandemic of 2020 when EVs were riding a cultural high, or Nvidia in the current AI boom, or even Figma. These companies don’t have enough yield, or, enough growth, or both - however - they are riding a trend. They have momentum. These can be more volatile - they don’t have the floor of strong cash flow
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -18% | Weak multi-year price returns2Y Excs Rtn is -104%, 3Y Excs Rtn is -146% | Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -24%, Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -22%, Rev Chg QQuarterly Revenue Change % is -19% |
| Attractive yieldFCF Yield is 8.0% | Meaningful short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 10% | Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -6.2% |
| Megatrend and thematic driversMegatrends include Healthcare Workforce Innovation, and Healthcare Talent & Labor Market Dynamics. Themes include Clinical Staffing Solutions, Integrated Workforce Management, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -18% |
| Attractive yieldFCF Yield is 8.0% |
| Megatrend and thematic driversMegatrends include Healthcare Workforce Innovation, and Healthcare Talent & Labor Market Dynamics. Themes include Clinical Staffing Solutions, Integrated Workforce Management, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -104%, 3Y Excs Rtn is -146% |
| Meaningful short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 10% |
| Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -24%, Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -22%, Rev Chg QQuarterly Revenue Change % is -19% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -6.2% |
Valuation, Metrics & Events
CCRN Stock
Why The Stock Moved
Qualitative Assessment
AI Generated Analysis | Feedback
For the approximate time period from August 31, 2025, to December 4, 2025, Cross Country Healthcare (CCRN) experienced a significant decline, attributed to several key factors.
1. Significant Revenue Decline in Third Quarter 2025
Cross Country Healthcare reported a substantial year-over-year decrease in revenue for the third quarter of 2025. Revenue was $202.0 million, representing a 24% decline year-over-year and 10% sequentially. Another report indicated a 29% year-over-year fall in revenue for the third quarter to $315.1 million. This significant contraction in the company's top line would have exerted considerable downward pressure on the stock.
2. Missed Earnings Estimates and Net Loss
The company posted a net loss of $4.77 million for the third quarter of 2025, a reversal from a net income in the same period the previous year. Earnings per share (EPS) for Q3 2025 came in at $0.03, missing analysts' consensus estimates of $0.04. Additionally, quarterly revenue of $250.05 million fell short of the consensus estimate of $270.72 million. These disappointing financial results likely contributed to a negative investor sentiment.
Stock Movement Drivers
Return vs. Risk
Price Returns Compared
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| CCRN Return | -24% | 213% | -4% | -15% | -20% | -45% | -13% |
| Peers Return | 13% | 5% | 9% | -1% | -12% | -15% | -4% |
| S&P 500 Return | 16% | 27% | -19% | 24% | 23% | 16% | 112% |
Monthly Win Rates [3] | |||||||
| CCRN Win Rate | 50% | 67% | 42% | 33% | 25% | 30% | |
| Peers Win Rate | 15% | 15% | 15% | 10% | 6% | 25% | |
| S&P 500 Win Rate | 58% | 75% | 42% | 67% | 75% | 70% | |
Max Drawdowns [4] | |||||||
| CCRN Max Drawdown | -59% | -2% | -43% | -32% | -57% | -41% | |
| Peers Max Drawdown | -16% | -0% | -4% | -5% | -13% | -16% | |
| S&P 500 Max Drawdown | -31% | -1% | -25% | -1% | -2% | -15% | |
[1] Cumulative total returns since the beginning of 2020
[2] Peers: ACHC, AMTU, AVG, MCTA, SRTA.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2025 data is for the year up to 12/3/2025 (YTD)
How Low Can It Go
| Event | CCRN | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -52.9% | -25.4% |
| % Gain to Breakeven | 112.4% | 34.1% |
| Time to Breakeven | Not Fully Recovered days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -59.1% | -33.9% |
| % Gain to Breakeven | 144.6% | 51.3% |
| Time to Breakeven | 291 days | 148 days |
| 2018 Correction | ||
| % Loss | -57.8% | -19.8% |
| % Gain to Breakeven | 137.0% | 24.7% |
| Time to Breakeven | 746 days | 120 days |
| 2008 Global Financial Crisis | ||
| % Loss | -77.3% | -56.8% |
| % Gain to Breakeven | 339.8% | 131.3% |
| Time to Breakeven | 4623 days | 1480 days |
Compare to ACHC, AMTU, AVG, MCTA, SRTA
In The Past
Cross Country Healthcare's stock fell -52.9% during the 2022 Inflation Shock from a high on 10/28/2022. A -52.9% loss requires a 112.4% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth over time.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
Trade Ideas
Select past ideas related to CCRN. For more, see Trefis Trade Ideas.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 11142025 | CRL | Charles River Laboratories International | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 4.1% | 4.1% | -3.7% |
| 11142025 | GDRX | GoodRx | Dip Buy | DB | CFO/Rev | Low D/EDip Buy with High Cash Flow MarginsBuying dips for companies with significant cash flows from operations and reasonable debt / market cap | -9.8% | -9.8% | -11.8% |
| 11142025 | ASTH | Astrana Health | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 6.0% | 6.0% | -5.5% |
| 11142025 | SGRY | Surgery Partners | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 9.7% | 9.7% | -1.4% |
| 11072025 | TFX | Teleflex | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 6.2% | 6.2% | -5.1% |
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 11142025 | CRL | Charles River Laboratories International | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 4.1% | 4.1% | -3.7% |
| 11142025 | GDRX | GoodRx | Dip Buy | DB | CFO/Rev | Low D/EDip Buy with High Cash Flow MarginsBuying dips for companies with significant cash flows from operations and reasonable debt / market cap | -9.8% | -9.8% | -11.8% |
| 11142025 | ASTH | Astrana Health | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 6.0% | 6.0% | -5.5% |
| 11142025 | SGRY | Surgery Partners | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 9.7% | 9.7% | -1.4% |
| 11072025 | TFX | Teleflex | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 6.2% | 6.2% | -5.1% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons for Cross Country Healthcare
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 9.45 |
| Mkt Cap | 0.8 |
| Rev LTM | 1,193 |
| Op Inc LTM | 11 |
| FCF LTM | -20 |
| FCF 3Y Avg | -32 |
| CFO LTM | 42 |
| CFO 3Y Avg | 174 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 4.6% |
| Rev Chg 3Y Avg | 9.0% |
| Rev Chg Q | 4.2% |
| QoQ Delta Rev Chg LTM | 1.1% |
| Op Mgn LTM | 0.9% |
| Op Mgn 3Y Avg | 4.3% |
| QoQ Delta Op Mgn LTM | -0.3% |
| CFO/Rev LTM | 3.5% |
| CFO/Rev 3Y Avg | 9.1% |
| FCF/Rev LTM | -7.7% |
| FCF/Rev 3Y Avg | -7.8% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 0.8 |
| P/S | 0.5 |
| P/EBIT | -39.1 |
| P/E | -15.0 |
| P/CFO | 8.4 |
| Total Yield | 1.4% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | 8.2% |
| D/E | 0.5 |
| Net D/E | 0.4 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | -23.2% |
| 3M Rtn | -26.2% |
| 6M Rtn | -30.7% |
| 12M Rtn | -40.3% |
| 3Y Rtn | -78.7% |
| 1M Excs Rtn | -23.2% |
| 3M Excs Rtn | -35.9% |
| 6M Excs Rtn | -45.4% |
| 12M Excs Rtn | -51.6% |
| 3Y Excs Rtn | -150.8% |
Segment Financials
Revenue by Segment
| $ Mil | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Nurse and Allied Staffing | 1,841 | 2,697 | 1,606 | 768 | 733 |
| Physician Staffing | 178 | 106 | 71 | 68 | 75 |
| Search | 15 | ||||
| Total | 2,020 | 2,803 | 1,677 | 836 | 822 |
| $ Mil | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Nurse and Allied Staffing | 197 | 352 | 206 | 74 | 64 |
| Physician Staffing | 10 | 6 | 4 | 4 | 3 |
| Acquisition and integration-related costs | -0 | -1 | |||
| Impairment charges | -1 | -6 | -2 | -16 | -16 |
| Legal and other losses | -1 | ||||
| Restructuring costs | -3 | -2 | -3 | -6 | -4 |
| Depreciation and amortization | -18 | -13 | -10 | -13 | -14 |
| Corporate overhead | -71 | -67 | -55 | -52 | -46 |
| Legal settlement charges | 0 | -2 | |||
| Other costs | -1 | -0 | -0 | ||
| Search | -1 | ||||
| Total | 113 | 270 | 139 | -9 | -16 |
Returns Analyses
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 6302025 | 8062025 | 10-Q 6/30/2025 |
| 3312025 | 5072025 | 10-Q 3/31/2025 |
| 12312024 | 3052025 | 10-K 12/31/2024 |
| 9302024 | 11072024 | 10-Q 9/30/2024 |
| 6302024 | 8012024 | 10-Q 6/30/2024 |
| 3312024 | 5022024 | 10-Q 3/31/2024 |
| 12312023 | 2232024 | 10-K 12/31/2023 |
| 9302023 | 11022023 | 10-Q 9/30/2023 |
| 6302023 | 8032023 | 10-Q 6/30/2023 |
| 3312023 | 5042023 | 10-Q 3/31/2023 |
| 12312022 | 2232023 | 10-K 12/31/2022 |
| 9302022 | 11032022 | 10-Q 9/30/2022 |
| 6302022 | 8042022 | 10-Q 6/30/2022 |
| 3312022 | 5052022 | 10-Q 3/31/2022 |
| 12312021 | 2282022 | 10-K 12/31/2021 |
| 9302021 | 11042021 | 10-Q 9/30/2021 |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |